Possible roles of growth factors and pancreatic hormones in the physiopathology of the non-alcoholic fatty liver disease
Main Article Content
Abstract
The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased paralleling with diabetes and metabolic syndrome. This trend has contributed to a surge in metabolic dysfunction–associated steatotic liver disease (MASLD), the most common chronic liver disease worldwide. NAFLD is defined by excessive triglycerides (TG) accumulation in hepatocytes, independent of alcohol consumption. Fatty liver arises from either increased TG delivery to the liver or carbohydrate conversion into TG. NAFLD shares key pathogenic mechanisms with metabolic syndrome, including obesity, hyperlipidemia, insulin resistance, mitochondrial dysfunction, oxidative stress, and inflammation. Two growth factors—Hepatocyte growth factor (HGF) and Epidermal growth factor (EGF)—may play significant roles in NAFLD pathophysiology. HGF interacts with insulin to regulate glucose metabolism in hepatocytes contributing to glucose homeostasis. EGF may also influence glucagon secretion by counteracting its suppression by plasma glucose, besides to be involved in liver cell proliferation. The known effects of these growth factors and hormones are largely loss at the onset of NAFLD. Therefore, this review explores the potential roles of HGF, EGF, and the pancreatic hormones insulin and glucagon in the NAFLD and evaluates their possible utility as biomarkers for diagnosis and therapeutic monitoring, since NAFLD, as an emerging disease, requires early detection and accurate prediction of disease progression for effective management.
Keywords:
Insulin, Glucagon, Triacylglycerols, Oxidant stress, Inflammation, FFA
Article Details
How to Cite
CONTRERAS-ZENTELLA, Martha Lucinda; HERNÁNDEZ-ESPINOSA, Lorena Carmina; HERNÁNDEZ-MUÑOZ, Rolando.
Possible roles of growth factors and pancreatic hormones in the physiopathology of the non-alcoholic fatty liver disease.
Medical Research Archives, [S.l.], v. 13, n. 10, oct. 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/7013>. Date accessed: 26 dec. 2025.
doi: https://doi.org/10.18103/mra.v13i10.7013.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1) Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212-2224.
2) Muhamad NA, Maamor NH, Leman FN, et al. The global prevalence of nonalcoholic fatty liver disease and its association with cancers: Systematic review and meta-analysis. Interact J Med Res. 2023;12:e40653. doi: 10.2196/40653.
3) Zahoor I, Mir GJ, Lone NA, Ashraf NU. Crosstalk between epigenetics and autophagy in metabolic dysfunction-associated steatotic liver disease. J Obes Metab Syndr. 2025;Jun 16. doi: 10.7570/ jomes24041.
4) Ashraf NU, Altaf M. Epigenetics: An emerging field in the pathogenesis of nonalcoholic fatty liver disease. Mutat Res Rev Mutat Res. 2018;778:1-12.
5) Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: Diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol. 2015;13(12):2062-2070.
6) Rinella ME, Lazarus JV, Ratziu V, et al. NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556.
7) Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91-100.
8) Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003;278(46): 45777-45784.
9) Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr. 2020;14(6):1875-1887.
10) Sun Y, Hu D, Yu M, et al. Diagnostic accuracy of non-Invasive diagnostic tests for nonalcoholic fatty liver disease: A systematic review and network meta-analysis. Clin Epidemiol. 2025;17:53-71.
11) Man S, Deng Y, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: A nationwide study with 5.7 million adults in China. Gastroenterology. 2023;165(4):1025-1040.
12) Wang JL, Jiang SW, Hu AR, et al. Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective. Heliyon. 2024;10(5):e27325. doi: 10.1016/j.heliyon.2024.e27325.
13) Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251(4995):802-804.
14) Marquardt JU, Seo D, Gómez-Quiroz LE, et al. Loss of c-Met accelerates development of liver fibrosis in response to CCl(4) exposure through deregulation of multiple molecular pathways. Biochim Biophys Acta. 2012;1822(6):942-951.
15) Fafalios A, Ma J, Tan X, et al. A hepatocyte growth factor receptor (Met)-insulin receptor hybrid governs hepatic glucose metabolism. Nat Med. 2011;17(12):1577-1584.
16) Akhtar S, Benter IF. The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction. Bioimpacts. 2013;3(1):5-9.
17) Song I, Patel O, Himpe E, Muller CJ, Bouwens L. Beta cell mass restoration in alloxan-diabetic mice treated with EGF and gastrin. PLoS One. 2015;10(1 0):e0140148. doi: 10.1371/journal.pone.0140148.
18) Contreras-Zentella ML, Alatriste-Contreras MG, Suárez-Cuenca JA, Hernández-Muñoz R. Gender effect of glucose, insulin/glucagon ratio, lipids, and nitrogen-metabolites on serum HGF and EGF levels in patients with diabetes type 2. Front Mol Biosci. 2024;11:1362305. doi: 10.3389/ fmolb.2024.1362305.
19) Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun. 1984;122(3):1450-1459.
20) Stolz DB, Mars WM, Petersen BE, Kim TH, Michalopoulos GK. Growth factor signal transduction immediately after two-thirds partial hepatectomy in the rat. Cancer Res. 1999;59(16):3954-3960.
21) Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11(12):834-848.
22) Zhang Y, Xia M, Jin K, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17(1):45. doi: 10.1186/s12943-018-0796-y.
23) Sakai K, Aoki S, Matsumoto K. Hepatocyte growth factor and Met in drug discovery. J Biochem. 2015;157(5):271-284.
24) Zhao Y, Ye W, Wang YD, Chen WD. HGF/c-Met: A key promoter in liver regeneration. Front Pharmacol. 2022;13:808855. doi: 10.3389/fphar.20 22.808855.
25) Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7(6):504-516.
26) Galimi F, Bagnara GP, Bonsi L, et al. Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors. J Cell Biol. 1994;127(6 Pt1):1743-1754.
27) Gallo S, Sala V, Gatti S, Crepaldi T. Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. Clin Sci (Lond). 2015;129 (12):1173-1193.
28) Cahill EF, Kennelly H, Carty F, Mahon BP, English K. Hepatocyte growth factor is required for mesenchymal stromal cell protection against bleomycin-Induced pulmonary fibrosis. Stem Cells Transl Med. 2016;5(10):1307-1318.
29) Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Vande Woude GF. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984;311 (5981):29-33.
30) Michalopoulos GK. Advances in liver regeneration. Expert Rev Gastroenterol Hepatol. 2014;8(8):897-907.
31) Mohammed FF, Khokha R. Thinking outside the cell: proteases regulate hepatocyte division. Trends Cell Biol. 2005;15(10):555-563.
32) Michalopoulos GK. Liver regeneration. J Cell Physiol. 2007;213(2):286-300.
33) Yanagita K, Nagaike M, Ishibashi H, Niho Y, Matsumoto K, Nakamura T. Lung may have an endocrine function producing hepatocyte growth factor in response to injury of distal organs. Biochem Biophys Res Commun. 1992;182(2):802-809.
34) Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005;121(7): 977-990. doi: 10.1016/j.cell.2005.04.014.
35) Ghanm SE, Shebl NA, El Sayed IET, Abdel-Bary HM, Saad BF, Othman Saad W. Direct relationship between interleukin-10 gene polymorphism and hepatocellular carcinoma complicated by direct acting antiviral treatment of hepatitis C virus. Asian Pac J Cancer Prev. 2021; 22(10):3203-3210.
36) El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273.e1.
37) Lai L, Chen J, Wei X, et al. Transplantation of MSCs overexpressing HGF into a rat model of liver fibrosis. Mol Imaging Biol. 2016;18(1):43-51.
38) Li Z, Mizuno S, Nakamura T. Antinecrotic and antiapoptotic effects of hepatocyte growth factor on cholestatic hepatitis in a mouse model of bile-obstructive diseases. Am J Physiol Gastrointest Liver Physiol. 2007;292(2):G639-646.
39) Kosai K, Matsumoto K, Funakoshi H, Nakamura T. Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology. 1999;30(1):151-159.
40) Yuge K, Takahashi T, Nagano S, et al. Adenoviral gene transduction of hepatocyte growth factor elicits inhibitory effects for hepatoma. Int J Oncol. 2005;27(1):77-85.
41) Hardesty JE, Wahlang B, Prough RA, Head KZ, Wilkey D, Merchant M, Shi H, Jin J, Cave MC. Effect of epidermal growth factor treatment and polychlorinated biphenyl exposure in a dietary-exposure mouse model of steatohepatitis. Environ Health Perspect. 2021;129(3):37010. doi: 10.1289/ EHP8222.
42) Xu H, Liu L, Cong M, Liu T, Sun S, Ma H. EGF neutralization antibodies attenuate liver fibrosis by inhibiting myofibroblast proliferation in bile duct ligation mice. Histochem Cell Biol. 2020;154 (1):107-116.
43) Modica TME, Dituri F, Mancarella S, Pisano C, Fabregat I, Giannelli G. Calcium regulates HCC proliferation as well as EGFR recycling/degradation and could be a new therapeutic target in HCC. Cancers (Basel). 2019;11(10):1588. doi: 10.3390/ cancers11101588.
44) Forrester SJ, Kawai T, O'Brien S, Thomas W, Harris RC, Eguchi S. Epidermal growth factor receptor transactivation: Mechanisms, pathophysiology, and potential therapies in the cardiovascular system. Annu Rev Pharmacol Toxicol. 2016;56:627-653.
45) Tito C, Masciarelli S, Colotti G, Fazi F. EGF receptor in organ development, tissue homeostasis and regeneration. J Biomed Sci. 2025;32(1):24. doi: 10.1186/s12929-025-01119-9.
46) Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3-20.
47) Singh B, Carpenter G, Coffey RJ. EGF receptor ligands: Recent advances. F1000Res. 2016;5:F1000 Faculty Rev-2270. doi:10.12688/f1000research.9025.1.
48) Wang Z. Transactivation of epidermal growth factor receptor by G Protein-Coupled Receptors: Recent progress, challenges and future research. Int J Mol Sci. 2016;17(1):95. doi: 10.3390/ijms 17010095.
49) López-Luque J, Caballero-Díaz D, Martinez-Palacián A, et al. Dissecting the role of epidermal growth factor receptor catalytic activity during liver regeneration and hepatocarcinogenesis. Hepatology. 2016;63(2):604-619.
50) Chen J, Zeng F, Forrester SJ, Eguchi S, Zhang MZ, Harris RC. Expression and function of the epidermal growth factor receptor in physiology and disease. Physiol Rev. 2016;96(3):1025-1069.
51) Cao S, Pan Y, Tang J, Terker AS, Arroyo Ornelas JP, et al. EGFR-mediated activation of adipose tissue macrophages promotes obesity and insulin resistance. Nat Commun. 2022;13(1):4684. doi: 10.1038/s41467-022-32348-3.
52) Orofiamma LA, Vural D, Antonescu CN. Control of cell metabolism by the epidermal growth factor receptor. Biochim Biophys Acta Mol Cell Res. 2022;1869(12):119359. doi: 10.1016/j.bb amcr.2022.119359.
53) Aydın MM, Akçalı KC. Liver fibrosis. Turk J Gastroenterol. 2018;29(1):14-21.
54) Shehata F, Abdel Monem N, Sakr M, Kasem S, Balbaa M. Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma. Med Oncol. 2013;30(3):673. doi: 10.1007/s12032-013-0673-x.
55) Bosch F, Bouscarel B, Slaton J, Blackmore PF, Exton JH. Epidermal growth factor mimics insulin effects in rat hepatocytes. Biochem J. 1986;239 (3):523-530.
56) Soler C, Galan X, Peinado-Onsurbe J, Quintana I, Llobera M, Ramírez I. Epidermal growth factor interferes with the effect of adrenaline on glucose production and on hepatic lipase secretion in rat hepatocytes. Regul Pept. 1993;44(1):11-16.
57) Peak M, Agius L. Inhibition of glycogen synthesis by epidermal growth factor in hepatocytes. The role of cell density and pertussis toxin-sensitive GTP-binding proteins. Eur J Biochem. 1994;221 (1):529-536.
58) Abu Rmilah AA, Zhou W, Nyberg SL. Hormonal contribution to liver regeneration. Mayo Clin Proc Innov Qual Outcomes. 2020;4(3):315-338.
59) Kimura M, Moteki H, Ogihara M. Role of hepatocyte growth regulators in liver regeneration. Cells. 2023;12(2):208. doi: 10.3390/cells12020208.
60) Tokarz VL, MacDonald PE, Klip A. The cell biology of systemic insulin function. J Cell Biol. 2018;217(7):2273-2289.
61) Ohlsson B, Jansen C, Ihse I, Axelson J. Epidermal growth factor induces cell proliferation in mouse pancreas and salivary glands. Pancreas. 1997;14(1):94-98.
62) Mehta DI, Horváth K, Chanasongcram S, Hill ID, Panigrahi P. Epidermal growth factor up-regulates sodium-glucose cotransport in enterocyte models in the presence of cholera toxin. JPEN J Parenter Enteral Nutr. 1997;21(4):185-191.
63) Schneider JA, Diamond I, Rozengurt E. Glycolysis of quiescent cultures of 3T3 cells. Addition of serum, epidermal growth factor, and insulin increases the activity of phosphofructokinase in a protein synthesis-independent manner. J Biol Chem. 1978;253(3):872-877.
64) Bosch F, Bouscarel B, Slaton J, Blackmore PF, Exton JH. Epidermal growth factor mimics insulin effects in rat hepatocytes. Biochem J. 1986;239 (3):523-530.
65) Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J. 1998;333(Pt3):471-490.
66) Mao SA, Glorioso JM, Nyberg SL. Liver regeneration. Transl Res. 2014;163(4):352-362.
67) Michalopoulos GK. Hepatostat: Liver regeneration and normal liver tissue maintenance. Hepatology. 2017;65(4):1384-1392.
68) Starzl TE, Porter KA, Putnam CW. Intraportal insulin protects from the liver injury of portacaval shunt in dogs. Lancet. 1975;2(7947):1241-1242.
69) Francavilla A, Di Leo A, Wu SQ, Ove P, Van Thiel D, Starzl TE. Discordance between glucokinase activity and insulin and glucagon receptor changes occurring during liver regeneration in the rat. Horm Metab Res. 1984;16 Suppl 1(Suppl 1):47-50.
70) Kimura M, Ogihara M. Proliferation of adult rat hepatocytes by hepatocyte growth factor is potentiated by both phenylephrine and metaproterenol. J Pharmacol Exp Ther. 1997;282(3):1146-1154.
71) Ito Y, Uchijima Y, Ariga M, Seki T, Takenaka A, Hakuno F, et al. Interaction between cAMP-dependent and insulin-dependent signal pathways in tyrosine phosphorylation in primary cultures of rat hepatocytes. Biochem J. 1997;324(Pt 2):379-388.
72) Amaya MJ, Oliveira AG, Guimarães ES, Casteluber MC, Carvalho SM, Andrade LM, et al. The insulin receptor translocates to the nucleus to regulate cell proliferation in liver. Hepatology. 2014;59(1):274-283.
73) Monaco L, Vicini E, Conti M. Structure of two rat genes coding for closely related rolipram-sensitive cAMP phosphodiesterases. Multiple mRNA variants originate from alternative splicing and multiple start sites. J Biol Chem. 1994;269 (1):347-357.
74) Xu J, Nakamura MT, Cho HP, Clarke SD. Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J Biol Chem. 1999;274(33):23577-23583.
75) Drucker DJ, Asa S. Glucagon gene expression in vertebrate brain. J Biol Chem. 1988;263(27): 13475-13478.
76) Rix I, Nexøe-Larsen C, Bergmann NC, Lund A, Knop FK. Glucagon Physiology. 2019 Jul 16. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al. editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.
77) Wewer Albrechtsen NJ, Holst JJ, Cherrington AD, Finan B, Gluud LL, et al. 100 years of glucagon and 100 more. Diabetologia. 2023;66(8):1378-1394.
78) Wewer Albrechtsen NJ, Kuhre RE, Pedersen J, Knop FK, Holst JJ. The biology of glucagon and the consequences of hyperglucagonemia. Biomark Med. 2016;10(11):1141-1151.
79) Campbell JE, Newgard CB. Mechanisms controlling pancreatic islet cell function in insulin secretion. Nat Rev Mol Cell Biol. 2021;22(2):142-158.
80) Svendsen B, Larsen O, Gabe MBN, Christiansen CB, Rosenkilde MM, Holst JJ. Insulin Secretion Depends on Intra-islet Glucagon Signaling. Cell Rep. 2018;25(5):1127-1134.e2.
81) Rorsman P, Huising MO. The somatostatin-secreting pancreatic δ-cell in health and disease. Nat Rev Endocrinol. 2018;14(7):404-414.
82) Strowski MZ, Parmar RM, Blake AD, Schaeffer JM. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology. 2000; 141(1):111-117.
83) Vergari E, Knudsen JG, Ramracheya R, Salehi A, Zhang Q, Adam J, et al. Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion. Nat Commun. 2019;10(1):139. doi: 10.1038/s41467-018-08193-8.
84) Andersen DB, Holst JJ. Peptides in the regulation of glucagon secretion. Peptides. 2022;1 48:170683. doi: 10.1016/j.peptides.2021.170683.
85) Wewer Albrechtsen NJ, Junker AE, Christensen M, Hædersdal S, Wibrand F, Lund AM, et al. Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes. Am J Physiol Gastrointest Liver Physiol. 2018;314(1):G91-G96.
86) Richter MM, Galsgaard KD, Elmelund E, Knop FK, Suppli MP, Holst JJ, et al. The Liver-α-Cell Axis in health and in disease. Diabetes. 2022;71(9): 1852-1861.
87) Rix I, Johansen ML, Lund A, Suppli MP, Chabanova E, van Hall G, Holst JJ, et al. Hyperglucagonaemia and amino acid alterations in individuals with type 2 diabetes and non-alcoholic fatty liver disease. Endocr Connect. 2023;13(1):e23 0161. doi: 10.1530/EC-23-0161.
88) Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201-223.
89) Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366): 1869-1881.
90) Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36.
91) Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as players and targets of therapies? Int J Mol Sci. 2021;22(10):5375. doi: 10.3390/ijms22105375.
92) Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr. 2020;14(6):1875-1887.
93) Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76(1):99-128.
94) Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343-1351.
95) Santoleri D, Titchenell PM. Resolving the paradox of hepatic insulin resistance. Cell Mol Gastroenterol Hepatol. 2019;7(2):447-456.
96) Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-867.
97) Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001;293 (5535):1673-1677.
98) Kuchay MS, Choudhary NS, Ramos-Molina B. Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease. Am J Physiol Cell Physiol. 2025;328(5):C1637-C1666.
99) Pina T, Armesto S, Lopez-Mejias R, Genre F, Ubilla B, Gonzalez-Lopez MA, et al. Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol. 2015;29(7): 1325-1330.
100) Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-Alcoholic Steatohepatitis: A review of its mechanism, models and medical treatments. Front Pharmacol. 2020 3;11:603926. doi: 10.3389/fphar.2020.603926.
101) Mostafavi Abdolmaleky H, Zhou JR. Gut Microbiota dysbiosis, oxidative stress, inflammation, and epigenetic alterations in metabolic diseases. Antioxidants (Basel). 2024;13(8):985. doi: 10.3390/ antiox13080985.
102) Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441 (7092):43143-43146.
103) White MF. Insulin signaling in health and disease. Science. 2003;302(5651):1710-1711.
104) Mooli RGR, Mukhi D, Ramakrishnan SK. Oxidative stress and redox signaling in the pathophysiology of liver diseases. Compr Physiol. 2022;12(2):3167-3192.
105) Iozzo P, Bucci M, Roivainen A, Någren K, Järvisalo MJ, Kiss J, et al. Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals. Gastroenterology. 2010;139(3):846-856.
106) Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012;52(1):59-69.
107) Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol. 2005;100(4):850-855.
108) Chen J, Schenker S, Frosto TA, Henderson GI. Inhibition of cytochrome c oxidase activity by 4-hydroxynonenal (HNE). Role of HNE adduct formation with the enzyme subunits. Biochim Biophys Acta. 1998;1380(3):336-344.
109) Grattagliano I, de Bari O, Bernardo TC, Oliveira PJ, Wang DQ, Portincasa P. Role of mitochondria in nonalcoholic fatty liver disease--from origin to propagation. Clin Biochem. 2012; 45(9):610-618.
110) Crespo J, Cayón A, Fernández-Gil P, Hernández-Guerra M, Mayorga M, Domínguez-Díez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001;34(6):1158-1163.
111) Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med. 2004;37(9):1499-1507.
112) Juárez-Fernández M, Goikoetxea-Usandizaga N, Porras D, García-Mediavilla MV, Bravo M, Serrano-Maciá M, et al. Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression. Hepatology. 2023;77 (5):1654-1669.
113) Goikoetxea-Usandizaga N, Serrano-Maciá M, Delgado TC, Simón J, Fernández Ramos D, Barriales D, et al. Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals. Hepatology. 2022;75(3):550-566.
114) Barbier-Torres L, Fortner KA, Iruzubieta P, Delgado TC, Giddings E, Chen Y, et al. Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation. Nat Commun. 2020;11(1):3360. doi: 10.1038/s41467-020-16991-2.
115) Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019;40(5):1367-1393.
116) Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78:181-205.
117) Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018l;24 (7):908-922.
118) Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16(6):377-386.
119) Singh A, Dhaliwal AS, Singh S, Kumar A, Lopez R, Gupta M, et al. Awareness of nonalcoholic fatty liver disease is increasing but remains very low in a representative US cohort. Dig Dis Sci. 2020;65(4):978-986.
120) Sriramdasu S, Sharma S, Ansari AR, Phatak NV, Tikoo K. Borneol ameliorates non-alcoholic fatty liver disease via promoting AMPK-mediated lipophagy. J Biochem Mol Toxicol. 2025;39(2):e70 182. doi: 10.1002/jbt.70182.
121) Zhang X, Ji X, Wang Q, Li JZ. New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Protein Cell. 2018;9(2):164-177.
122) George H, Permata FS, D'Souza CM, Adeghate EA. Cultural and molecular factors predisposed to non-alcoholic fatty liver disease and type 2 diabetes mellitus. Nutrients. 2025;17 (11):1797. doi: 10.3390/nu17111797.
123) Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol. 2018;13:321-350.
124) Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56(3):943-951.
125) Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987-1000.
126) Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):179-185.
127) Ghorpade DS, Ozcan L, Zheng Z, Nicoloro SM, Shen Y, Chen E, et al. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature. 2018;555(7698):673-677.
128) Martinez-Lopez N, Singh R. Autophagy and lipid droplets in the liver. Annu Rev Nutr. 2015; 35:215-237.
129) Liu HY, Han J, Cao SY, Hong T, Zhuo D, Shi J, et al. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J Biol Chem. 2009; 284(45):31484-31492.
130) Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32-42.
131) Pina T, Genre F, Lopez-Mejias R, Armesto S, Ubilla B, Mijares V, et al. Anti-TNF-α therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol. 2016;30(1):92-95.
132) Luc K, Schramm-Luc A, Guzik TJ, Mikolajczyk TP. Oxidative stress and inflammatory markers in prediabetes and diabetes. J Physiol Pharmacol. 2019;70(6). doi: 10.26402/jpp.2019.6.01.
133) Byun S, Seok S, Kim YC, Zhang Y, Yau P, Iwamori N, et al. Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase. Nat Commun. 2020;11(1):807. doi: 10.1038/s41467-020-14384-z.
134) Min Y, Zhang Y, Ji Y, Liu S, Guan C, Wei L, et al. Post-translational modifications in the pathophysiological process of metabolic dysfunction‑associated steatotic liver disease. Cell Biosci. 2025;15(1):79. doi: 10.1186/s13578-025-01411-z.
135) Ren H, Hu F, Wang D, Kang X, Feng X, Zhang L, et al. Sirtuin 2 prevents liver steatosis and metabolic disorders by deacetylation of Hepatocyte Nuclear Factor 4α. Hepatology. 2021; 74(2):723-740.
136) Targher G, Mantovani A, Byrne CD. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2023;8(2):179-191.
137) Junker AE, Gluud L, Holst JJ, Knop FK, Vilsbøll T. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. J Intern Med. 2016;279(5):485-493.
138) Wewer Albrechtsen NJ, Pedersen J, Galsgaard KD, Winther-Sørensen M, Suppli MP, Janah L, et al. The Liver-α-Cell Axis and Type 2 Diabetes. Endocr Rev. 2019;40(5):1353-1366.
139) Suppli MP, Bagger JI, Lund A, Demant M, van Hall G, Strandberg C, et al. Glucagon resistance at the level of amino acid turnover in obese subjects with hepatic steatosis. Diabetes. 2020;69(6):1090-1099.
140) Wewer Albrechtsen NJ. Glucagon receptor signaling in metabolic diseases. Peptides. 2018; 100:42-47.
141) Grandt J, Jensen AH, Werge MP, Rashu EB, Møller A, Junker AE, et al. Postprandial dysfunction in fatty liver disease. Physiol Rep. 2023;11(8):e1565 3. doi: 10.14814/phy2.15653.
142) Heebøll S, Risikesan J, Ringgaard S, Kumarathas I, Sandahl TD, Grønbæk H, et al. Impaired glucagon-mediated suppression of VLDL-Triglyceride secretion in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD). Diabetes. 2022;71(11):2402-2411.
143) Gerich JE, Lorenzi M, Bier DM, Schneider V, Tsalikian E, Forsham PH. Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N Engl J Med. 1975;292(19):985-989.
144) Allaire M, Gilgenkrantz H. The impact of steatosis on liver regeneration. Horm Mol Biol Clin Investig. 2018;41(1):/j/hmbci.2020.41.issue-1/hmb ci-2018-0050/hmbci-2018-0050.xml. doi: 10.1515/ hmbci-2018-0050.
145) Truant S, Bouras AF, Petrovai G, Buob D, Ernst O, Boleslawski E, et al. Volumetric gain of the liver after major hepatectomy in obese patients: a case-matched study in 84 patients. Ann Surg. 2013;258(5):696-702.
146) Collin de l'Hortet A, Zerrad-Saadi A, Prip-Buus C, Fauveau V, Helmy N, Ziol M, et al. GH administration rescues fatty liver regeneration impairment by restoring GH/EGFR pathway deficiency. Endocrinology. 2014;155(7):2545-2554.
147) Bhushan B, Banerjee S, Paranjpe S, Koral K, Mars WM, Stoops JW, et al. Pharmacologic inhibition of epidermal growth factor receptor suppresses nonalcoholic fatty liver disease in a murine fast-food diet model. Hepatology. 2019; 70(5):1546-1563.
148) Leclercq IA, Field J, Farrell GC. Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injury. Gastroenterology. 2003;124(5):1451-1464.
149) Gentric G, Maillet V, Paradis V, Couton D, L'Hermitte A, Panasyuk G, et al. Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease. J Clin Invest. 2015;125(3):981-992.
150) Shao F, Deng H, Zhang W, Ren Z, Kang Z, Ding Z, et al. Loss of EGFR contributes to high-fat diet-induced nonalcoholic fatty liver disease. FEBS Lett. 2023;597(11):1503-1516.
151) Wang Y, Lam KS, Xu JY, Lu G, Xu LY, Xu A. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem. 2005;280(18):18341-18347.
152) Matsuzawa Y. The metabolic syndrome and adipocytokines. Expert Rev Clin Immunol. 2007;3(1 ):39-46.
153) Kim S, Subramanian V, Abdel-Latif A, Lee S. Role of Heparin-Binding Epidermal Growth Factor-like growth factor in oxidative stress-associated metabolic diseases. Metab Syndr Relat Disord. 2020;18(4):186-196.
154) Duan JL, Ruan B, Yan XC, Liang L, Song P, Yang ZY, et al. Endothelial Notch activation reshapes the angiocrine of sinusoidal endothelia to aggravate liver fibrosis and blunt regeneration in mice. Hepatology. 2018;68(2):677-690.
155) Lovric A, Granér M, Bjornson E, Arif M, Benfeitas R, Nyman K, et al. Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome. Sci Rep. 2018;8(1):14200. doi: 10.1038/s41598-018-31865-w.
156) Kim SJ, Kim SJ, Hyun J, Kim HW, Jang JH. Regeneration of non-alcoholic fatty liver cells using chimeric FGF21/HGFR: A novel therapeutic approach. Int J Mol Sci. 2024;25(6):3092. doi: 10.3390/ijms25063092.
157) Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med. 1999;5(2):226-230.
158) Li N, Dou Z, Liu J, Chai B, Li Y, An X, et al. Therapeutic effect of HGF on NASH mice through HGF/c-Met and JAK2-STAT3 signalling pathway. Ann Hepatol. 2018;17(3):501-510.
159) Narmada BC, Kang Y, Venkatraman L, Peng Q, Sakban RB, Nugraha B, et al. Hepatic stellate cell-targeted delivery of hepatocyte growth factor transgene via bile duct infusion enhances its expression at fibrotic foci to regress dimethylnitrosamine-induced liver fibrosis. Hum Gene Ther. 2013; 24(5):508-519.
160) Czaja AJ, Carpenter HA. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol. 2007;5(8):898-907.
161) Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology. 2009;49(3):1017-1044.
162) Corpechot C, Poujol-Robert A, Wendum D, Galotte M, Chrétien Y, Poupon R. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int. 2004;24(3):187-193.
163) Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem. 2006;52(10):1887-1896.
164) Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehman RL. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology. 2008;47(1):332-342.
165) Jarcuska P, Janicko M, Veselíny E, Jarcuska P, Skladaný L. Circulating markers of liver fibrosis progression. Clin Chim Acta. 2010;411(15-16):1009-1017.
166) Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22 (6):696-699.
167) European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021; 75(3):659-689.
168) Mózes FE, Lee JA, Vali Y, Alzoubi O, Staufer K, Trauner M, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2023; 8(8):704-713.
169) Watt J, Kurth MJ, Reid CN, Lamont JV, Fitzgerald P, Ruddock MW. Non-alcoholic fatty liver disease-A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease. Front Physiol. 2022;13: 963513. doi: 10.3389/fphys.2022.963513.
170) Kurth MJ, McBride WT, McLean G, Watt J, Domanska A, Lamont JV, et al. Acute kidney injury risk in orthopaedic trauma patients pre and post surgery using a biomarker algorithm and clinical risk score. Sci Rep. 2020;10(1):20005. doi: 10.1038 /s41598-020-76929-y.
171) Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.
172) Kechagias S, Ekstedt M, Simonsson C, Nasr P. Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. Hormones (Athens). 2022;21(3):349-368.
173) Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 2020;73(2):252-262.
174) Wang M, Wang X, Wang Y, Gai Y, Ye J, You X. Advances in the study of the mechanism of action of miR‑22 in liver lesions (Review). Oncol Lett. 2024;28(5):541. doi: 10.3892/ol.2024.14674.
175) Hardy T, Zeybel M, Day CP, Dipper C, Masson S, McPherson S, et al. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut. 2017l; 66(7):1321-1328.
176) Hochreuter MY, Dall M, Treebak JT, Barrès R. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives. Mol Metab. 2022;65: 101581. doi: 10.1016/j.molmet.2022.101581.
177) Hendy OM, Rabie H, El Fouly A, Abdel-Samiee M, Abdelmotelb N, Elshormilisy AA, et al. The circulating micro-RNAs (-122, -34a and -99a) as predictive biomarkers for non-alcoholic fatty liver diseases. Diabetes Metab Syndr Obes. 2019;12: 2715-2723.
178) Chen C, Xie L, Zhang M, Shama, Cheng KKY, Jia W. The interplay between the muscle and liver in the regulation of glucolipid metabolism. J Mol Cell Biol. 2024;15(12):mjad073. doi: 10.1093/ jmcb/mjad073.
179) Langan D. Assessing Heterogeneity in Random-Effects Meta-analysis. Methods Mol Biol. 2022;2345:67-89.
180) Mukhuty A, Fouzder C, Kundu R. Fetuin-A secretion from β-cells leads to accumulation of macrophages in islets, aggravates inflammation and impairs insulin secretion. J Cell Sci. 2021; 134(21):jcs258507. doi: 10.1242/jcs.258507.
181) Feng Y, Luo S, Fang C, Ma S, Fan D, Chen Y, et al. ANGPTL8 deficiency attenuates lipopolysaccharide-induced liver injury by improving lipid metabolic dysregulation. J Lipid Res. 2024;65 (8):100595. doi: 10.1016/j.jlr.2024.100595.
182) Kong Y, Zhao C, Tan P, Liu S, Huang Y, Zeng F, et al. FGF21 reduces lipid accumulation in bovine hepatocytes by enhancing lipid oxidation and reducing lipogenesis via AMPK signaling. Animals (Basel). 2022;12(7):939. doi: 10.3390/ani12070939.
183) Zhu Q, Li H, Ao Z, Xu H, Luo J, Kaurich C, et al. Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis. J Nanobiotechnology. 2022;20(1):349. doi: 10.118 6/s12951-022-01540-4.
184) Radmanić L, Zidovec-Lepej S. The role of stem cell factor, epidermal growth factor and angiopoietin-2 in HBV, HCV, HCC and NAFLD. Life (Basel). 2022;12(12):2072. doi: 10.3390/life12122072.
185) Abozaid YJ, Ayada I, van Kleef LA, Vallerga CL, Pan Q, Brouwer WP, et al. Plasma proteomic signature of fatty liver disease: The Rotterdam Study. Hepatology. 2023;78(1):284-294.
2) Muhamad NA, Maamor NH, Leman FN, et al. The global prevalence of nonalcoholic fatty liver disease and its association with cancers: Systematic review and meta-analysis. Interact J Med Res. 2023;12:e40653. doi: 10.2196/40653.
3) Zahoor I, Mir GJ, Lone NA, Ashraf NU. Crosstalk between epigenetics and autophagy in metabolic dysfunction-associated steatotic liver disease. J Obes Metab Syndr. 2025;Jun 16. doi: 10.7570/ jomes24041.
4) Ashraf NU, Altaf M. Epigenetics: An emerging field in the pathogenesis of nonalcoholic fatty liver disease. Mutat Res Rev Mutat Res. 2018;778:1-12.
5) Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: Diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol. 2015;13(12):2062-2070.
6) Rinella ME, Lazarus JV, Ratziu V, et al. NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556.
7) Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91-100.
8) Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003;278(46): 45777-45784.
9) Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr. 2020;14(6):1875-1887.
10) Sun Y, Hu D, Yu M, et al. Diagnostic accuracy of non-Invasive diagnostic tests for nonalcoholic fatty liver disease: A systematic review and network meta-analysis. Clin Epidemiol. 2025;17:53-71.
11) Man S, Deng Y, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: A nationwide study with 5.7 million adults in China. Gastroenterology. 2023;165(4):1025-1040.
12) Wang JL, Jiang SW, Hu AR, et al. Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective. Heliyon. 2024;10(5):e27325. doi: 10.1016/j.heliyon.2024.e27325.
13) Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251(4995):802-804.
14) Marquardt JU, Seo D, Gómez-Quiroz LE, et al. Loss of c-Met accelerates development of liver fibrosis in response to CCl(4) exposure through deregulation of multiple molecular pathways. Biochim Biophys Acta. 2012;1822(6):942-951.
15) Fafalios A, Ma J, Tan X, et al. A hepatocyte growth factor receptor (Met)-insulin receptor hybrid governs hepatic glucose metabolism. Nat Med. 2011;17(12):1577-1584.
16) Akhtar S, Benter IF. The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction. Bioimpacts. 2013;3(1):5-9.
17) Song I, Patel O, Himpe E, Muller CJ, Bouwens L. Beta cell mass restoration in alloxan-diabetic mice treated with EGF and gastrin. PLoS One. 2015;10(1 0):e0140148. doi: 10.1371/journal.pone.0140148.
18) Contreras-Zentella ML, Alatriste-Contreras MG, Suárez-Cuenca JA, Hernández-Muñoz R. Gender effect of glucose, insulin/glucagon ratio, lipids, and nitrogen-metabolites on serum HGF and EGF levels in patients with diabetes type 2. Front Mol Biosci. 2024;11:1362305. doi: 10.3389/ fmolb.2024.1362305.
19) Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun. 1984;122(3):1450-1459.
20) Stolz DB, Mars WM, Petersen BE, Kim TH, Michalopoulos GK. Growth factor signal transduction immediately after two-thirds partial hepatectomy in the rat. Cancer Res. 1999;59(16):3954-3960.
21) Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11(12):834-848.
22) Zhang Y, Xia M, Jin K, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17(1):45. doi: 10.1186/s12943-018-0796-y.
23) Sakai K, Aoki S, Matsumoto K. Hepatocyte growth factor and Met in drug discovery. J Biochem. 2015;157(5):271-284.
24) Zhao Y, Ye W, Wang YD, Chen WD. HGF/c-Met: A key promoter in liver regeneration. Front Pharmacol. 2022;13:808855. doi: 10.3389/fphar.20 22.808855.
25) Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7(6):504-516.
26) Galimi F, Bagnara GP, Bonsi L, et al. Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors. J Cell Biol. 1994;127(6 Pt1):1743-1754.
27) Gallo S, Sala V, Gatti S, Crepaldi T. Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. Clin Sci (Lond). 2015;129 (12):1173-1193.
28) Cahill EF, Kennelly H, Carty F, Mahon BP, English K. Hepatocyte growth factor is required for mesenchymal stromal cell protection against bleomycin-Induced pulmonary fibrosis. Stem Cells Transl Med. 2016;5(10):1307-1318.
29) Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Vande Woude GF. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984;311 (5981):29-33.
30) Michalopoulos GK. Advances in liver regeneration. Expert Rev Gastroenterol Hepatol. 2014;8(8):897-907.
31) Mohammed FF, Khokha R. Thinking outside the cell: proteases regulate hepatocyte division. Trends Cell Biol. 2005;15(10):555-563.
32) Michalopoulos GK. Liver regeneration. J Cell Physiol. 2007;213(2):286-300.
33) Yanagita K, Nagaike M, Ishibashi H, Niho Y, Matsumoto K, Nakamura T. Lung may have an endocrine function producing hepatocyte growth factor in response to injury of distal organs. Biochem Biophys Res Commun. 1992;182(2):802-809.
34) Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005;121(7): 977-990. doi: 10.1016/j.cell.2005.04.014.
35) Ghanm SE, Shebl NA, El Sayed IET, Abdel-Bary HM, Saad BF, Othman Saad W. Direct relationship between interleukin-10 gene polymorphism and hepatocellular carcinoma complicated by direct acting antiviral treatment of hepatitis C virus. Asian Pac J Cancer Prev. 2021; 22(10):3203-3210.
36) El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273.e1.
37) Lai L, Chen J, Wei X, et al. Transplantation of MSCs overexpressing HGF into a rat model of liver fibrosis. Mol Imaging Biol. 2016;18(1):43-51.
38) Li Z, Mizuno S, Nakamura T. Antinecrotic and antiapoptotic effects of hepatocyte growth factor on cholestatic hepatitis in a mouse model of bile-obstructive diseases. Am J Physiol Gastrointest Liver Physiol. 2007;292(2):G639-646.
39) Kosai K, Matsumoto K, Funakoshi H, Nakamura T. Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology. 1999;30(1):151-159.
40) Yuge K, Takahashi T, Nagano S, et al. Adenoviral gene transduction of hepatocyte growth factor elicits inhibitory effects for hepatoma. Int J Oncol. 2005;27(1):77-85.
41) Hardesty JE, Wahlang B, Prough RA, Head KZ, Wilkey D, Merchant M, Shi H, Jin J, Cave MC. Effect of epidermal growth factor treatment and polychlorinated biphenyl exposure in a dietary-exposure mouse model of steatohepatitis. Environ Health Perspect. 2021;129(3):37010. doi: 10.1289/ EHP8222.
42) Xu H, Liu L, Cong M, Liu T, Sun S, Ma H. EGF neutralization antibodies attenuate liver fibrosis by inhibiting myofibroblast proliferation in bile duct ligation mice. Histochem Cell Biol. 2020;154 (1):107-116.
43) Modica TME, Dituri F, Mancarella S, Pisano C, Fabregat I, Giannelli G. Calcium regulates HCC proliferation as well as EGFR recycling/degradation and could be a new therapeutic target in HCC. Cancers (Basel). 2019;11(10):1588. doi: 10.3390/ cancers11101588.
44) Forrester SJ, Kawai T, O'Brien S, Thomas W, Harris RC, Eguchi S. Epidermal growth factor receptor transactivation: Mechanisms, pathophysiology, and potential therapies in the cardiovascular system. Annu Rev Pharmacol Toxicol. 2016;56:627-653.
45) Tito C, Masciarelli S, Colotti G, Fazi F. EGF receptor in organ development, tissue homeostasis and regeneration. J Biomed Sci. 2025;32(1):24. doi: 10.1186/s12929-025-01119-9.
46) Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3-20.
47) Singh B, Carpenter G, Coffey RJ. EGF receptor ligands: Recent advances. F1000Res. 2016;5:F1000 Faculty Rev-2270. doi:10.12688/f1000research.9025.1.
48) Wang Z. Transactivation of epidermal growth factor receptor by G Protein-Coupled Receptors: Recent progress, challenges and future research. Int J Mol Sci. 2016;17(1):95. doi: 10.3390/ijms 17010095.
49) López-Luque J, Caballero-Díaz D, Martinez-Palacián A, et al. Dissecting the role of epidermal growth factor receptor catalytic activity during liver regeneration and hepatocarcinogenesis. Hepatology. 2016;63(2):604-619.
50) Chen J, Zeng F, Forrester SJ, Eguchi S, Zhang MZ, Harris RC. Expression and function of the epidermal growth factor receptor in physiology and disease. Physiol Rev. 2016;96(3):1025-1069.
51) Cao S, Pan Y, Tang J, Terker AS, Arroyo Ornelas JP, et al. EGFR-mediated activation of adipose tissue macrophages promotes obesity and insulin resistance. Nat Commun. 2022;13(1):4684. doi: 10.1038/s41467-022-32348-3.
52) Orofiamma LA, Vural D, Antonescu CN. Control of cell metabolism by the epidermal growth factor receptor. Biochim Biophys Acta Mol Cell Res. 2022;1869(12):119359. doi: 10.1016/j.bb amcr.2022.119359.
53) Aydın MM, Akçalı KC. Liver fibrosis. Turk J Gastroenterol. 2018;29(1):14-21.
54) Shehata F, Abdel Monem N, Sakr M, Kasem S, Balbaa M. Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma. Med Oncol. 2013;30(3):673. doi: 10.1007/s12032-013-0673-x.
55) Bosch F, Bouscarel B, Slaton J, Blackmore PF, Exton JH. Epidermal growth factor mimics insulin effects in rat hepatocytes. Biochem J. 1986;239 (3):523-530.
56) Soler C, Galan X, Peinado-Onsurbe J, Quintana I, Llobera M, Ramírez I. Epidermal growth factor interferes with the effect of adrenaline on glucose production and on hepatic lipase secretion in rat hepatocytes. Regul Pept. 1993;44(1):11-16.
57) Peak M, Agius L. Inhibition of glycogen synthesis by epidermal growth factor in hepatocytes. The role of cell density and pertussis toxin-sensitive GTP-binding proteins. Eur J Biochem. 1994;221 (1):529-536.
58) Abu Rmilah AA, Zhou W, Nyberg SL. Hormonal contribution to liver regeneration. Mayo Clin Proc Innov Qual Outcomes. 2020;4(3):315-338.
59) Kimura M, Moteki H, Ogihara M. Role of hepatocyte growth regulators in liver regeneration. Cells. 2023;12(2):208. doi: 10.3390/cells12020208.
60) Tokarz VL, MacDonald PE, Klip A. The cell biology of systemic insulin function. J Cell Biol. 2018;217(7):2273-2289.
61) Ohlsson B, Jansen C, Ihse I, Axelson J. Epidermal growth factor induces cell proliferation in mouse pancreas and salivary glands. Pancreas. 1997;14(1):94-98.
62) Mehta DI, Horváth K, Chanasongcram S, Hill ID, Panigrahi P. Epidermal growth factor up-regulates sodium-glucose cotransport in enterocyte models in the presence of cholera toxin. JPEN J Parenter Enteral Nutr. 1997;21(4):185-191.
63) Schneider JA, Diamond I, Rozengurt E. Glycolysis of quiescent cultures of 3T3 cells. Addition of serum, epidermal growth factor, and insulin increases the activity of phosphofructokinase in a protein synthesis-independent manner. J Biol Chem. 1978;253(3):872-877.
64) Bosch F, Bouscarel B, Slaton J, Blackmore PF, Exton JH. Epidermal growth factor mimics insulin effects in rat hepatocytes. Biochem J. 1986;239 (3):523-530.
65) Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J. 1998;333(Pt3):471-490.
66) Mao SA, Glorioso JM, Nyberg SL. Liver regeneration. Transl Res. 2014;163(4):352-362.
67) Michalopoulos GK. Hepatostat: Liver regeneration and normal liver tissue maintenance. Hepatology. 2017;65(4):1384-1392.
68) Starzl TE, Porter KA, Putnam CW. Intraportal insulin protects from the liver injury of portacaval shunt in dogs. Lancet. 1975;2(7947):1241-1242.
69) Francavilla A, Di Leo A, Wu SQ, Ove P, Van Thiel D, Starzl TE. Discordance between glucokinase activity and insulin and glucagon receptor changes occurring during liver regeneration in the rat. Horm Metab Res. 1984;16 Suppl 1(Suppl 1):47-50.
70) Kimura M, Ogihara M. Proliferation of adult rat hepatocytes by hepatocyte growth factor is potentiated by both phenylephrine and metaproterenol. J Pharmacol Exp Ther. 1997;282(3):1146-1154.
71) Ito Y, Uchijima Y, Ariga M, Seki T, Takenaka A, Hakuno F, et al. Interaction between cAMP-dependent and insulin-dependent signal pathways in tyrosine phosphorylation in primary cultures of rat hepatocytes. Biochem J. 1997;324(Pt 2):379-388.
72) Amaya MJ, Oliveira AG, Guimarães ES, Casteluber MC, Carvalho SM, Andrade LM, et al. The insulin receptor translocates to the nucleus to regulate cell proliferation in liver. Hepatology. 2014;59(1):274-283.
73) Monaco L, Vicini E, Conti M. Structure of two rat genes coding for closely related rolipram-sensitive cAMP phosphodiesterases. Multiple mRNA variants originate from alternative splicing and multiple start sites. J Biol Chem. 1994;269 (1):347-357.
74) Xu J, Nakamura MT, Cho HP, Clarke SD. Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J Biol Chem. 1999;274(33):23577-23583.
75) Drucker DJ, Asa S. Glucagon gene expression in vertebrate brain. J Biol Chem. 1988;263(27): 13475-13478.
76) Rix I, Nexøe-Larsen C, Bergmann NC, Lund A, Knop FK. Glucagon Physiology. 2019 Jul 16. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al. editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.
77) Wewer Albrechtsen NJ, Holst JJ, Cherrington AD, Finan B, Gluud LL, et al. 100 years of glucagon and 100 more. Diabetologia. 2023;66(8):1378-1394.
78) Wewer Albrechtsen NJ, Kuhre RE, Pedersen J, Knop FK, Holst JJ. The biology of glucagon and the consequences of hyperglucagonemia. Biomark Med. 2016;10(11):1141-1151.
79) Campbell JE, Newgard CB. Mechanisms controlling pancreatic islet cell function in insulin secretion. Nat Rev Mol Cell Biol. 2021;22(2):142-158.
80) Svendsen B, Larsen O, Gabe MBN, Christiansen CB, Rosenkilde MM, Holst JJ. Insulin Secretion Depends on Intra-islet Glucagon Signaling. Cell Rep. 2018;25(5):1127-1134.e2.
81) Rorsman P, Huising MO. The somatostatin-secreting pancreatic δ-cell in health and disease. Nat Rev Endocrinol. 2018;14(7):404-414.
82) Strowski MZ, Parmar RM, Blake AD, Schaeffer JM. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology. 2000; 141(1):111-117.
83) Vergari E, Knudsen JG, Ramracheya R, Salehi A, Zhang Q, Adam J, et al. Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion. Nat Commun. 2019;10(1):139. doi: 10.1038/s41467-018-08193-8.
84) Andersen DB, Holst JJ. Peptides in the regulation of glucagon secretion. Peptides. 2022;1 48:170683. doi: 10.1016/j.peptides.2021.170683.
85) Wewer Albrechtsen NJ, Junker AE, Christensen M, Hædersdal S, Wibrand F, Lund AM, et al. Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes. Am J Physiol Gastrointest Liver Physiol. 2018;314(1):G91-G96.
86) Richter MM, Galsgaard KD, Elmelund E, Knop FK, Suppli MP, Holst JJ, et al. The Liver-α-Cell Axis in health and in disease. Diabetes. 2022;71(9): 1852-1861.
87) Rix I, Johansen ML, Lund A, Suppli MP, Chabanova E, van Hall G, Holst JJ, et al. Hyperglucagonaemia and amino acid alterations in individuals with type 2 diabetes and non-alcoholic fatty liver disease. Endocr Connect. 2023;13(1):e23 0161. doi: 10.1530/EC-23-0161.
88) Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201-223.
89) Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366): 1869-1881.
90) Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36.
91) Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as players and targets of therapies? Int J Mol Sci. 2021;22(10):5375. doi: 10.3390/ijms22105375.
92) Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr. 2020;14(6):1875-1887.
93) Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76(1):99-128.
94) Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343-1351.
95) Santoleri D, Titchenell PM. Resolving the paradox of hepatic insulin resistance. Cell Mol Gastroenterol Hepatol. 2019;7(2):447-456.
96) Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-867.
97) Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001;293 (5535):1673-1677.
98) Kuchay MS, Choudhary NS, Ramos-Molina B. Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease. Am J Physiol Cell Physiol. 2025;328(5):C1637-C1666.
99) Pina T, Armesto S, Lopez-Mejias R, Genre F, Ubilla B, Gonzalez-Lopez MA, et al. Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol. 2015;29(7): 1325-1330.
100) Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-Alcoholic Steatohepatitis: A review of its mechanism, models and medical treatments. Front Pharmacol. 2020 3;11:603926. doi: 10.3389/fphar.2020.603926.
101) Mostafavi Abdolmaleky H, Zhou JR. Gut Microbiota dysbiosis, oxidative stress, inflammation, and epigenetic alterations in metabolic diseases. Antioxidants (Basel). 2024;13(8):985. doi: 10.3390/ antiox13080985.
102) Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441 (7092):43143-43146.
103) White MF. Insulin signaling in health and disease. Science. 2003;302(5651):1710-1711.
104) Mooli RGR, Mukhi D, Ramakrishnan SK. Oxidative stress and redox signaling in the pathophysiology of liver diseases. Compr Physiol. 2022;12(2):3167-3192.
105) Iozzo P, Bucci M, Roivainen A, Någren K, Järvisalo MJ, Kiss J, et al. Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals. Gastroenterology. 2010;139(3):846-856.
106) Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012;52(1):59-69.
107) Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol. 2005;100(4):850-855.
108) Chen J, Schenker S, Frosto TA, Henderson GI. Inhibition of cytochrome c oxidase activity by 4-hydroxynonenal (HNE). Role of HNE adduct formation with the enzyme subunits. Biochim Biophys Acta. 1998;1380(3):336-344.
109) Grattagliano I, de Bari O, Bernardo TC, Oliveira PJ, Wang DQ, Portincasa P. Role of mitochondria in nonalcoholic fatty liver disease--from origin to propagation. Clin Biochem. 2012; 45(9):610-618.
110) Crespo J, Cayón A, Fernández-Gil P, Hernández-Guerra M, Mayorga M, Domínguez-Díez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001;34(6):1158-1163.
111) Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med. 2004;37(9):1499-1507.
112) Juárez-Fernández M, Goikoetxea-Usandizaga N, Porras D, García-Mediavilla MV, Bravo M, Serrano-Maciá M, et al. Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression. Hepatology. 2023;77 (5):1654-1669.
113) Goikoetxea-Usandizaga N, Serrano-Maciá M, Delgado TC, Simón J, Fernández Ramos D, Barriales D, et al. Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals. Hepatology. 2022;75(3):550-566.
114) Barbier-Torres L, Fortner KA, Iruzubieta P, Delgado TC, Giddings E, Chen Y, et al. Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation. Nat Commun. 2020;11(1):3360. doi: 10.1038/s41467-020-16991-2.
115) Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019;40(5):1367-1393.
116) Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78:181-205.
117) Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018l;24 (7):908-922.
118) Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16(6):377-386.
119) Singh A, Dhaliwal AS, Singh S, Kumar A, Lopez R, Gupta M, et al. Awareness of nonalcoholic fatty liver disease is increasing but remains very low in a representative US cohort. Dig Dis Sci. 2020;65(4):978-986.
120) Sriramdasu S, Sharma S, Ansari AR, Phatak NV, Tikoo K. Borneol ameliorates non-alcoholic fatty liver disease via promoting AMPK-mediated lipophagy. J Biochem Mol Toxicol. 2025;39(2):e70 182. doi: 10.1002/jbt.70182.
121) Zhang X, Ji X, Wang Q, Li JZ. New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Protein Cell. 2018;9(2):164-177.
122) George H, Permata FS, D'Souza CM, Adeghate EA. Cultural and molecular factors predisposed to non-alcoholic fatty liver disease and type 2 diabetes mellitus. Nutrients. 2025;17 (11):1797. doi: 10.3390/nu17111797.
123) Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol. 2018;13:321-350.
124) Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56(3):943-951.
125) Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987-1000.
126) Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):179-185.
127) Ghorpade DS, Ozcan L, Zheng Z, Nicoloro SM, Shen Y, Chen E, et al. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature. 2018;555(7698):673-677.
128) Martinez-Lopez N, Singh R. Autophagy and lipid droplets in the liver. Annu Rev Nutr. 2015; 35:215-237.
129) Liu HY, Han J, Cao SY, Hong T, Zhuo D, Shi J, et al. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J Biol Chem. 2009; 284(45):31484-31492.
130) Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32-42.
131) Pina T, Genre F, Lopez-Mejias R, Armesto S, Ubilla B, Mijares V, et al. Anti-TNF-α therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol. 2016;30(1):92-95.
132) Luc K, Schramm-Luc A, Guzik TJ, Mikolajczyk TP. Oxidative stress and inflammatory markers in prediabetes and diabetes. J Physiol Pharmacol. 2019;70(6). doi: 10.26402/jpp.2019.6.01.
133) Byun S, Seok S, Kim YC, Zhang Y, Yau P, Iwamori N, et al. Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase. Nat Commun. 2020;11(1):807. doi: 10.1038/s41467-020-14384-z.
134) Min Y, Zhang Y, Ji Y, Liu S, Guan C, Wei L, et al. Post-translational modifications in the pathophysiological process of metabolic dysfunction‑associated steatotic liver disease. Cell Biosci. 2025;15(1):79. doi: 10.1186/s13578-025-01411-z.
135) Ren H, Hu F, Wang D, Kang X, Feng X, Zhang L, et al. Sirtuin 2 prevents liver steatosis and metabolic disorders by deacetylation of Hepatocyte Nuclear Factor 4α. Hepatology. 2021; 74(2):723-740.
136) Targher G, Mantovani A, Byrne CD. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2023;8(2):179-191.
137) Junker AE, Gluud L, Holst JJ, Knop FK, Vilsbøll T. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. J Intern Med. 2016;279(5):485-493.
138) Wewer Albrechtsen NJ, Pedersen J, Galsgaard KD, Winther-Sørensen M, Suppli MP, Janah L, et al. The Liver-α-Cell Axis and Type 2 Diabetes. Endocr Rev. 2019;40(5):1353-1366.
139) Suppli MP, Bagger JI, Lund A, Demant M, van Hall G, Strandberg C, et al. Glucagon resistance at the level of amino acid turnover in obese subjects with hepatic steatosis. Diabetes. 2020;69(6):1090-1099.
140) Wewer Albrechtsen NJ. Glucagon receptor signaling in metabolic diseases. Peptides. 2018; 100:42-47.
141) Grandt J, Jensen AH, Werge MP, Rashu EB, Møller A, Junker AE, et al. Postprandial dysfunction in fatty liver disease. Physiol Rep. 2023;11(8):e1565 3. doi: 10.14814/phy2.15653.
142) Heebøll S, Risikesan J, Ringgaard S, Kumarathas I, Sandahl TD, Grønbæk H, et al. Impaired glucagon-mediated suppression of VLDL-Triglyceride secretion in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD). Diabetes. 2022;71(11):2402-2411.
143) Gerich JE, Lorenzi M, Bier DM, Schneider V, Tsalikian E, Forsham PH. Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N Engl J Med. 1975;292(19):985-989.
144) Allaire M, Gilgenkrantz H. The impact of steatosis on liver regeneration. Horm Mol Biol Clin Investig. 2018;41(1):/j/hmbci.2020.41.issue-1/hmb ci-2018-0050/hmbci-2018-0050.xml. doi: 10.1515/ hmbci-2018-0050.
145) Truant S, Bouras AF, Petrovai G, Buob D, Ernst O, Boleslawski E, et al. Volumetric gain of the liver after major hepatectomy in obese patients: a case-matched study in 84 patients. Ann Surg. 2013;258(5):696-702.
146) Collin de l'Hortet A, Zerrad-Saadi A, Prip-Buus C, Fauveau V, Helmy N, Ziol M, et al. GH administration rescues fatty liver regeneration impairment by restoring GH/EGFR pathway deficiency. Endocrinology. 2014;155(7):2545-2554.
147) Bhushan B, Banerjee S, Paranjpe S, Koral K, Mars WM, Stoops JW, et al. Pharmacologic inhibition of epidermal growth factor receptor suppresses nonalcoholic fatty liver disease in a murine fast-food diet model. Hepatology. 2019; 70(5):1546-1563.
148) Leclercq IA, Field J, Farrell GC. Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injury. Gastroenterology. 2003;124(5):1451-1464.
149) Gentric G, Maillet V, Paradis V, Couton D, L'Hermitte A, Panasyuk G, et al. Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease. J Clin Invest. 2015;125(3):981-992.
150) Shao F, Deng H, Zhang W, Ren Z, Kang Z, Ding Z, et al. Loss of EGFR contributes to high-fat diet-induced nonalcoholic fatty liver disease. FEBS Lett. 2023;597(11):1503-1516.
151) Wang Y, Lam KS, Xu JY, Lu G, Xu LY, Xu A. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem. 2005;280(18):18341-18347.
152) Matsuzawa Y. The metabolic syndrome and adipocytokines. Expert Rev Clin Immunol. 2007;3(1 ):39-46.
153) Kim S, Subramanian V, Abdel-Latif A, Lee S. Role of Heparin-Binding Epidermal Growth Factor-like growth factor in oxidative stress-associated metabolic diseases. Metab Syndr Relat Disord. 2020;18(4):186-196.
154) Duan JL, Ruan B, Yan XC, Liang L, Song P, Yang ZY, et al. Endothelial Notch activation reshapes the angiocrine of sinusoidal endothelia to aggravate liver fibrosis and blunt regeneration in mice. Hepatology. 2018;68(2):677-690.
155) Lovric A, Granér M, Bjornson E, Arif M, Benfeitas R, Nyman K, et al. Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome. Sci Rep. 2018;8(1):14200. doi: 10.1038/s41598-018-31865-w.
156) Kim SJ, Kim SJ, Hyun J, Kim HW, Jang JH. Regeneration of non-alcoholic fatty liver cells using chimeric FGF21/HGFR: A novel therapeutic approach. Int J Mol Sci. 2024;25(6):3092. doi: 10.3390/ijms25063092.
157) Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med. 1999;5(2):226-230.
158) Li N, Dou Z, Liu J, Chai B, Li Y, An X, et al. Therapeutic effect of HGF on NASH mice through HGF/c-Met and JAK2-STAT3 signalling pathway. Ann Hepatol. 2018;17(3):501-510.
159) Narmada BC, Kang Y, Venkatraman L, Peng Q, Sakban RB, Nugraha B, et al. Hepatic stellate cell-targeted delivery of hepatocyte growth factor transgene via bile duct infusion enhances its expression at fibrotic foci to regress dimethylnitrosamine-induced liver fibrosis. Hum Gene Ther. 2013; 24(5):508-519.
160) Czaja AJ, Carpenter HA. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol. 2007;5(8):898-907.
161) Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology. 2009;49(3):1017-1044.
162) Corpechot C, Poujol-Robert A, Wendum D, Galotte M, Chrétien Y, Poupon R. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int. 2004;24(3):187-193.
163) Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem. 2006;52(10):1887-1896.
164) Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehman RL. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology. 2008;47(1):332-342.
165) Jarcuska P, Janicko M, Veselíny E, Jarcuska P, Skladaný L. Circulating markers of liver fibrosis progression. Clin Chim Acta. 2010;411(15-16):1009-1017.
166) Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22 (6):696-699.
167) European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021; 75(3):659-689.
168) Mózes FE, Lee JA, Vali Y, Alzoubi O, Staufer K, Trauner M, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2023; 8(8):704-713.
169) Watt J, Kurth MJ, Reid CN, Lamont JV, Fitzgerald P, Ruddock MW. Non-alcoholic fatty liver disease-A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease. Front Physiol. 2022;13: 963513. doi: 10.3389/fphys.2022.963513.
170) Kurth MJ, McBride WT, McLean G, Watt J, Domanska A, Lamont JV, et al. Acute kidney injury risk in orthopaedic trauma patients pre and post surgery using a biomarker algorithm and clinical risk score. Sci Rep. 2020;10(1):20005. doi: 10.1038 /s41598-020-76929-y.
171) Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.
172) Kechagias S, Ekstedt M, Simonsson C, Nasr P. Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. Hormones (Athens). 2022;21(3):349-368.
173) Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 2020;73(2):252-262.
174) Wang M, Wang X, Wang Y, Gai Y, Ye J, You X. Advances in the study of the mechanism of action of miR‑22 in liver lesions (Review). Oncol Lett. 2024;28(5):541. doi: 10.3892/ol.2024.14674.
175) Hardy T, Zeybel M, Day CP, Dipper C, Masson S, McPherson S, et al. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut. 2017l; 66(7):1321-1328.
176) Hochreuter MY, Dall M, Treebak JT, Barrès R. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives. Mol Metab. 2022;65: 101581. doi: 10.1016/j.molmet.2022.101581.
177) Hendy OM, Rabie H, El Fouly A, Abdel-Samiee M, Abdelmotelb N, Elshormilisy AA, et al. The circulating micro-RNAs (-122, -34a and -99a) as predictive biomarkers for non-alcoholic fatty liver diseases. Diabetes Metab Syndr Obes. 2019;12: 2715-2723.
178) Chen C, Xie L, Zhang M, Shama, Cheng KKY, Jia W. The interplay between the muscle and liver in the regulation of glucolipid metabolism. J Mol Cell Biol. 2024;15(12):mjad073. doi: 10.1093/ jmcb/mjad073.
179) Langan D. Assessing Heterogeneity in Random-Effects Meta-analysis. Methods Mol Biol. 2022;2345:67-89.
180) Mukhuty A, Fouzder C, Kundu R. Fetuin-A secretion from β-cells leads to accumulation of macrophages in islets, aggravates inflammation and impairs insulin secretion. J Cell Sci. 2021; 134(21):jcs258507. doi: 10.1242/jcs.258507.
181) Feng Y, Luo S, Fang C, Ma S, Fan D, Chen Y, et al. ANGPTL8 deficiency attenuates lipopolysaccharide-induced liver injury by improving lipid metabolic dysregulation. J Lipid Res. 2024;65 (8):100595. doi: 10.1016/j.jlr.2024.100595.
182) Kong Y, Zhao C, Tan P, Liu S, Huang Y, Zeng F, et al. FGF21 reduces lipid accumulation in bovine hepatocytes by enhancing lipid oxidation and reducing lipogenesis via AMPK signaling. Animals (Basel). 2022;12(7):939. doi: 10.3390/ani12070939.
183) Zhu Q, Li H, Ao Z, Xu H, Luo J, Kaurich C, et al. Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis. J Nanobiotechnology. 2022;20(1):349. doi: 10.118 6/s12951-022-01540-4.
184) Radmanić L, Zidovec-Lepej S. The role of stem cell factor, epidermal growth factor and angiopoietin-2 in HBV, HCV, HCC and NAFLD. Life (Basel). 2022;12(12):2072. doi: 10.3390/life12122072.
185) Abozaid YJ, Ayada I, van Kleef LA, Vallerga CL, Pan Q, Brouwer WP, et al. Plasma proteomic signature of fatty liver disease: The Rotterdam Study. Hepatology. 2023;78(1):284-294.